The multinational Pipeline Analysis of Hospital Acquired Pneumonia Drugs market had reached xxx million USD with a CAGR xx from 2015-2019. Later on, it will go to xxx million USD in 2020 with a CAGR xx % from 2020 to 2025.
Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne.
In the global Pipeline Analysis of Hospital Acquired Pneumonia Drugs market, This report focuses particularly in North America, South America, Europe and Asia-Pacific, and Middle East and Africa. This report classifies the market on the basis of application, type, regions, and manufactures.
In market segmentation by manufacturers, the report covers the following companies-
Achaogen
Aridis Pharmaceuticals
AstraZeneca
Cubist Pharmaceuticals
Meiji Seika Pharma
Merck
Sanofi
GlaxoSmithKline
Valneva
In market segmentation by geographical regions, the report has analysed the following regions-
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Columbia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
In market segmentation by types :
Tedizolid Phosphate
Ceftolozane/Tazobactam
Ceftazidime/Avibactum
Amikacin Inhale
Plazomicin
Synflorix Vaccine
In market segmentation by applications :
Bacterial Pneumonia
Viral Pneumonia
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Pipeline Analysis of Hospital Acquired Pneumonia Drugs market for the forecast period 2020 - 2025?
• What are the driving forces in the Pipeline Analysis of Hospital Acquired Pneumonia Drugs market for the forecast period 2020 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Pipeline Analysis of Hospital Acquired Pneumonia Drugs industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?